[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Guidelines Synopsis
August 11, 2015

Screening for Chronic Kidney Disease

Author Affiliations
  • 1Section of Hospital Medicine, Department of Medicine, University of Chicago, Chicago, Illinois
  • 2Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(6):615-616. doi:10.1001/jama.2015.9425

Chronic kidney disease is an important health issue associated with increased morbidity, mortality, and health care costs. Chronic kidney disease is defined as greater than 3 months of decreased kidney function, identified by a reduced estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 or by blood or urine markers of kidney damage regardless of eGFR.1 Using this definition, about which there remains some controversy, more than 14% of the US population has CKD and 6% have stage 3 CKD or higher.2,3 Stage 3 CKD confers a greater risk of CKD-related complications and progression to end-stage renal disease (ESRD).3 Because CKD has a long asymptomatic phase, there are acceptable screening tests, and the health consequences associated with the disease are high, it is a disease that is amenable to screening. Screening could also be beneficial because only 10% of people with CKD know they have the disease, and treatments exist that delay the progression of CKD.4